REBECCA STEELE: Open Payments
NPI 1871349589 · DOVER, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 36 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $394 · 2025 $702
Food & beverage: $603Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $212 |
| GlaxoSmithKline, LLC. | 11 | $148 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
| GENZYME CORPORATION | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| BioCryst US Sales Co., LLC | 1 | $34 |
| CSL Behring | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
Products named: DUPIXENT, AIRSUPRA, FASENRA, NUCALA, TRELEGY ELLIPTA, ORLADEYO, BREZTRI, XOLAIR.
Industry payments across DE — which companies pay providers there.
